Michael J Littau1, Sujay Kulshrestha2, Corinne Bunn2, Sonya Agnew3, Patrick Sweigert2, Fred A Luchette3, Marshall S Baker4. 1. Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA. 2. Department of Surgery, Loyola University Medical Center, Maywood, IL, USA. 3. Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA; Department of Surgery, Loyola University Medical Center, Maywood, IL, USA; Edward Hines Jr., Veterans Administration Medical Center, Hines, IL, USA. 4. Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA; Department of Surgery, Loyola University Medical Center, Maywood, IL, USA; Edward Hines Jr., Veterans Administration Medical Center, Hines, IL, USA. Electronic address: marshall.baker@lumc.edu.
Abstract
BACKGROUND: Prior studies evaluating the impact of adjuvant or neoadjuvant radiation on clinical outcomes of patients with non-lipomatous retroperitoneal sarcoma have been underpowered. METHODS: We queried the National Cancer Database to identify patients undergoing surgical resection of retroperitoneal sarcoma with non-lipomatous histology from 2004 to 2016. Multivariable logistic regression and Cox proportional hazards modelling with patients stratified by tumor size were used to identify factors associated with overall survival. RESULTS: 3,394 patients met inclusion criteria. 592 had small (<5 cm), 1,186 had intermediate (5-10 cm), and 1,616 had large (>10 cm) tumors. Use of either neoadjuvant or adjuvant radiotherapy was associated with improved survival for patients with intermediate (neoadjuvant HR 0.67, CI [0.46, 0.98]; adjuvant HR 0.61, CI [0.50, 0.76]) and large (neoadjuvant HR 0.50, CI [0.37, 0.68]; adjuvant HR 0.56, CI [0.47, 0.69]) tumors, while adjuvant radiation therapy was associated with a survival benefit for small-sized tumors (HR 0.67, CI [0.46, 0.99]). CONCLUSIONS: Radiation therapy is associated with an overall survival benefit in patients presenting undergoing resection of non-lipomatous retroperitoneal sarcoma.
BACKGROUND: Prior studies evaluating the impact of adjuvant or neoadjuvant radiation on clinical outcomes of patients with non-lipomatous retroperitoneal sarcoma have been underpowered. METHODS: We queried the National Cancer Database to identify patients undergoing surgical resection of retroperitoneal sarcoma with non-lipomatous histology from 2004 to 2016. Multivariable logistic regression and Cox proportional hazards modelling with patients stratified by tumor size were used to identify factors associated with overall survival. RESULTS: 3,394 patients met inclusion criteria. 592 had small (<5 cm), 1,186 had intermediate (5-10 cm), and 1,616 had large (>10 cm) tumors. Use of either neoadjuvant or adjuvant radiotherapy was associated with improved survival for patients with intermediate (neoadjuvant HR 0.67, CI [0.46, 0.98]; adjuvant HR 0.61, CI [0.50, 0.76]) and large (neoadjuvant HR 0.50, CI [0.37, 0.68]; adjuvant HR 0.56, CI [0.47, 0.69]) tumors, while adjuvant radiation therapy was associated with a survival benefit for small-sized tumors (HR 0.67, CI [0.46, 0.99]). CONCLUSIONS: Radiation therapy is associated with an overall survival benefit in patients presenting undergoing resection of non-lipomatous retroperitoneal sarcoma.
Authors: Konstantinos Chouliaras; Rebecca Senehi; Cecilia G Ethun; George Poultsides; Valerie Grignol; Callisia N Clarke; Kevin K Roggin; Ryan C Fields; Patrick B Schwartz; Sean M Ronnekleiv-Kelly; Ralph D'Agostino; Emily N Johnson; Edward A Levine; Kenneth Cardona; Konstantinos I Votanopoulos Journal: J Surg Oncol Date: 2019-09-04 Impact factor: 3.454
Authors: Konstantinos Chouliaras; Rebecca Senehi; Cecilia G Ethun; George Poultsides; Thuy Tran; Valerie Grignol; Thomas Clark Gamblin; Kevin K Roggin; Jennifer Tseng; Ryan C Fields; Sharon M Weber; Gregory B Russell; Edward A Levine; Kenneth Cardona; Konstantinos Votanopoulos Journal: J Surg Oncol Date: 2019-06-27 Impact factor: 3.454
Authors: Daniel P Nussbaum; Christel N Rushing; Whitney O Lane; Diana M Cardona; David G Kirsch; Bercedis L Peterson; Dan G Blazer Journal: Lancet Oncol Date: 2016-05-17 Impact factor: 41.316
Authors: Jennifer L Leiting; John R Bergquist; Matthew C Hernandez; Kenneth W Merrell; Andrew L Folpe; Steven I Robinson; David M Nagorney; Mark J Truty; Travis E Grotz Journal: Sarcoma Date: 2018-12-05